These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36186839)

  • 1. Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran.
    Sahebari M; Mirfeizi Z; Shariati-Sarabi Z; Dadgar Moghadam M; Hashemzadeh K; Firoozabadi M
    Reumatologia; 2022; 60(4):231-241. PubMed ID: 36186839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.
    Sahebari M; Mirfeizi Z; Hashemzadeh K; Salavati Nik E; Gholampoor Shamkani N
    Arch Bone Jt Surg; 2022 Nov; 10(11):964-968. PubMed ID: 36561225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs.
    Yousefghahari B; Navari S; Sadeghi M; Soleimaniamiri S; Soleimaniamiri M; Heidari B; Babaei M; Ghodrati K; Guran A; Gholinia H
    Clin Rheumatol; 2021 Oct; 40(10):4309-4315. PubMed ID: 34052904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.
    McKeigue PM; Porter D; Hollick RJ; Ralston SH; McAllister DA; Colhoun HM
    Scand J Rheumatol; 2023 Jul; 52(4):412-417. PubMed ID: 35549809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.
    Hung MH; Tien YC; Chiu YM
    Adv Rheumatol; 2021 Apr; 61(1):22. PubMed ID: 33832541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey.
    Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN
    Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
    Esatoglu SN; Tascilar K; Babaoğlu H; Bes C; Yurttas B; Akar S; Pehlivan O; Akleylek C; Tecer D; Seyahi E; Yuce-Inel T; Alpay-Kanitez N; Bodakci E; Tekgoz E; Colak S; Bolek EC; Koca SS; Kalyoncu U; Icacan OC; Ugurlu S; Oz HE; Hamuryudan V; Hatemi G;
    Front Immunol; 2021; 12():651715. PubMed ID: 33936073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
    Kardeş S; Kuzu AS; Pakhchanian H; Raiker R; Karagülle M
    Clin Rheumatol; 2021 May; 40(5):2047-2055. PubMed ID: 33130946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and Disease-Modifying Anti-rheumatic Drugs.
    D'Silva KM; Wallace ZS
    Curr Rheumatol Rep; 2021 Apr; 23(5):28. PubMed ID: 33893890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.
    Moradi S; Masoumi M; Mohammadi S; Vafaeimanesh J; Mohseni M; Mahdavi H; Aryannejad A
    Intern Emerg Med; 2021 Jun; 16(4):919-923. PubMed ID: 33128696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
    Ahmadinejad Z; Assari R; Ayoobi Yazdi N; Mazloomi SH; Javanshayani P; Khalili Afousi H; Ziaee V
    Reumatismo; 2020 Nov; 72(3):173-177. PubMed ID: 33213130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
    Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in rheumatic disease patients on immunosuppressive agents.
    Sharmeen S; Elghawy A; Zarlasht F; Yao Q
    Semin Arthritis Rheum; 2020 Aug; 50(4):680-686. PubMed ID: 32512263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
    Favalli A; Favalli EG; Gobbini A; Zagato E; Bombaci M; Maioli G; Pesce E; Donnici L; Gruarin P; Biggioggero M; Curti S; Manganaro L; Marchisio E; Bevilacqua V; Martinovic M; Fabbris T; Sarnicola ML; Crosti M; Marongiu L; Granucci F; Notarbartolo S; Bandera A; Gori A; De Francesco R; Abrignani S; Caporali R; Grifantini R
    Front Immunol; 2022; 13():873195. PubMed ID: 35757699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anxiety and Depression in Rheumatoid Arthritis Patients Treating with Disease-Modifying Anti-Rheumatic Drugs during the COVID-19 Pandemic.
    Sargın G; Baygin H; Senturk T
    Mediterr J Rheumatol; 2022 Dec; 33(4):430-436. PubMed ID: 37034363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.
    Soy M; Keser G; Atagunduz P; Mutlu MY; Gunduz A; Koybaşi G; Bes C
    Clin Rheumatol; 2021 Sep; 40(9):3533-3545. PubMed ID: 33751280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
    Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
    Mourouzis IS; Manolis AS; Pantos C
    Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
    Favalli EG; Monti S; Ingegnoli F; Balduzzi S; Caporali R; Montecucco C
    Arthritis Rheumatol; 2020 Oct; 72(10):1600-1606. PubMed ID: 32506699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.